BioXcel Therapeutics, Inc.
BTAIQ · OTCMCIK 1720893fmd_1TK0AHR0AHDHEY9EHWRZFZ0R38Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Jun 30, 2026, 38 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 0 | 1 | 2 | 1 |
| Cost of revenue | – | – | – | – | – | 0 | 1 | 2 | 0 |
| Gross profit | – | – | – | – | – | 0 | 0 | 0 | 0 |
| Research and development | 3 | 15 | 26 | 58 | 53 | 91 | 84 | 30 | 30 |
| Selling, general and administrative | – | – | – | – | 54 | 69 | 83 | 34 | 20 |
| Total operating expenses | 5 | 20 | 34 | 82 | 107 | – | – | – | – |
| Operating income | (5) | (20) | (34) | (82) | (107) | (160) | (172) | (67) | (50) |
| Interest expense | – | – | 0 | 0 | 0 | 8 | 13 | 15 | 17 |
| Interest and investment income | – | – | – | 0 | 0 | 3 | 6 | 3 | 1 |
| Other non-operating income (expense) | – | – | – | – | – | (0) | 0 | 20 | (4) |
| Income tax expense | – | – | – | – | – | – | 0 | 0 | 0 |
| Net income | (5) | (19) | (33) | (82) | (107) | (166) | (179) | (60) | (70) |